BCAN's Patient Insight Webinar series includes the four-part Veterans & Bladder Cancer Webinar, which focused on the physical and emotional impact of bladder cancer unique to our veteran population. You can watch each video below.
Medical Breakdown
Common Psychological Issues
Navigating Veterans Affairs
Question and Answer Sessions
In March 2016, the Institute of Medicine, a division of the National Academies of Sciences, evaluated the available scientific and medical information about possible health effects, including bladder cancer, due to exposure to Agent Orange and other herbicides used in Vietnam.
This report changed bladder cancer's category of association with exposure to Agent Orange, moving from "inadequate or insufficient" evidence of association, up to "limited or suggestive" evidence of association.
Why It Matters
Bladder cancer's reclassification calls for more research for this disease, and brings it one step closer to being added to the Department of Veterans Affairs' presumptive list.
This means veterans with bladder cancer due to herbicide exposure could possibly receive benefits from the VA.
In July 2015, the VA released a report warning past residents of Marin Corps Base Camp Lejeune of their potential exposure to drinking water contaminated with industrial solvents, benzene, and other chemicals.
Fifteen health conditions, including bladder cancer, have been linked to this exposure, and qualify for VA health benefits.
If you lived on Camp Lejeune for longer than 30 days between August 1, 1952 and December 1, 1987, contact your local VA healthcare facility to start the enrollment process.
FDA Approves Encorafenib Plus Cetuximab and Chemo in BRAF V600E-Positive Metastatic CRC
Published: December 20th 2024 | Updated: December 20th 2024The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation.